3 Undervalued Life Sciences Tools & Services Stocks for Monday, November 11
Discover the top 3 undervalued Life Sciences Tools & Services stocks for Monday, November 11 based on AAII’s Stock Grades.Omar Beirat
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Omar Beirat
Omar Beirat
Jack Gilleland
Jack Gilleland
| Share Statistics | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $16.1 | $3,832.8 | 9% |
|
| Shares Out (Mil) | 11.5 | 101.8 | 23% |
|
| Institutional Ownership | 99.1% | 88.3% | 85% |
|
| Float (Mil) | 10.6 | 79.7 | 20% |
|
| Beta | 1.64 | 1.19 | 86% |
|
| Avg Daily Volume (000s) | 257 | 953 | 48% |
|
| Price Change (52-week) |
(30.1%) | 83.6% | 30% |
|
| Growth | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 27.4% | 7.5% | 88% |
|
| Net Income (5yr) | 8.5% | (11.2%) | 53% |
|
| EPS (5yr) | 54.0% | 2.5% | 94 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (14.9%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.450) | ($2.140) | ($0.970) | |
| Month Ago EPS | ($0.450) | ($2.140) | ($0.970) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.420) | ($2.130) | ($0.970) | |
| Year/Year Chg | (30.0%) | (55.9%) | (89.3%) | |
| Financials | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $30 | $800 | 16% |
|
| Net Income (TTM) (Mil) | ($32) | ($32) | 20% |
|
| EPS (TTM) | ($3.371) | ($0.300) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($21) | $47 | 15% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $6 | 45% |
|
| Long-Term Debt (Q1) (Mil) | $6 | $263 | 25% |
|
| Enterprise Value (Q1) (Mil) | $16 | $3,587 | 10% |
|
| Valuation | BNGO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.51 | 3.56 | 10% |
|
| P/E | na | 43.9 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.1 | na |
|
| Ratios | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 47.5% | 47.7% | 59% |
|
| Net Margin | (106.6%) | (6.0%) | 7% |
|
| ROA | (52.0%) | (4.8%) | 11% |
|
| ROE | (83.6%) | (7.9%) | 11% |
|
| Liabilities to Assets | 33.6% | 41.0% | 25% |
|
| F-Score | 5 | 5 | 50% |
|
Bionano Genomics, Inc. did not pass any screens on 10/14/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors